SEC Form 4 · accession 0001114220-18-000064
KERYX BIOPHARMACEUTICALS INC · KERX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kevin J Cameron
Director
Period of report
Jun 15, 2018
Accepted (ET)
Jun 18, 2018 · 6:39 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001114220
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 15, 2018 | M | 10,000 | $0.48 | A | 178,333 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F2 | $0.48 | Jun 15, 2018 | M | 10,000 | D | Jun 18, 2008 | Jun 18, 2018 | Common Stock | 10,000 | 0 | D |
Explanation of responses
- F1Includes 9,999 shares of restricted stock.
- F2The stock options vested according to the following schedule: one-half of the 10,000 options vested on June 18, 2008 and one-half vested on June 18, 2009.